ArticleMedicine2025
Transverse myelitis as a rare paraneoplastic manifestation of a pancreatic tail adenocarcinoma: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unusual Manifestations of Primary Pancreatic Neoplasia.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleTransverse myelitis (TM) is a non-compressive myelopathy caused by spinal cord inflammation that can present with motor, sensory and autonomic deficits. Paraneoplastic TM represents a rare etiology of TM caused by autoantibodies targeting the spinal cord in the setting of malignancy, most frequently lung cancers and lymphoproliferative disorders. Anti-glutamic acid decarboxylase 65 (GAD65) is a rare antibody associated with paraneoplastic neurological sequelae. This case presents a GAD65 positive paraneoplastic TM in the setting of a pancreatic tail adenocarcinoma. PATIENT CONCERNS: A 51-year-old male with an 18.5 pack year smoking history presented for 4 months of progressively worsening left-sided weakness and back pain. He endorsed numbness, tremors and paresthesias of his left upper extremity, left lower extremity weakness with unsteady gait. DIAGNOSES: Magnetic resonance imaging demonstrated C4-T1 demyelination consistent with TM. The serum paraneoplastic panel revealed a positive GAD65 prompting further workup for occult malignancy. Computed tomography chest abdomen and pelvis and magnetic resonance imaging with magnetic resonance cholangiopancreatography showed pancreatic body and tail enlargement. A pancreatic tail mass was confirmed on endoscopic ultrasound. Pathology was consistent with pancreatic ductal adenocarcinoma, confirming the diagnosis of a paraneoplastic TM.
interventionsHe received 5 days of methylprednisolone (1.0 g daily) and plasmapheresis for initial treatment of his TM and 5 days of methylprednisolone for his repeat episode. He was being treated for stage III T4N1 pancreatic cancer. He had completed 2 cycles of oxaliplatin, irinotecan, leucovorin, and 5-flurouracil (mFOLFIRINOX). OUTCOMES: The patient initially had improvement in his neurological symptoms following the first chemotherapy cycle but developed quadriparesis requiring readmission for subacute TM. He transitioned to hospice care given progression of malignancy. LESSONS: This case highlights the importance of GAD65 as a paraneoplastic antibody and promotes awareness of pancreatic tail adenocarcinoma as a rare cause of paraneoplastic TM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.